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E11/Podoplanin (Pdpn) is implicated in early osteocytogenesis and the formation of osteo-
cyte dendrites. This dendritic network is critical for bone modelling/remodelling, through
the production of receptor activator of nuclear factor κ B (RANK)-ligand (RANKL). Despite
this, the role of Pdpn in the control of bone remodelling is yet to be established in vivo.
Here we utilised bone-specific Pdpn conditional knockout mice (cKO) to examine the role
of Pdpn in the bone loss associated with ovariectomy (OVX). MicroCT revealed that Pdpn
deletion had no significant effect on OVX-induced changes in trabecular microarchitecture.
Significant differences between genotypes were observed in the trabecular pattern factor
(P<0.01) and structure model index (P<0.01). Phalloidin staining of F-actin revealed OVX
to induce alterations in osteocyte morphology in both wild-type (WT) and cKO mice. Histo-
logical analysis revealed an expected significant increase in osteoclast number in WT mice
(P<0.01, compared with sham). However, cKO mice were protected against such increases
in osteoclast number. Consistent with this, serum levels of the bone resorption marker Ctx
were significantly increased in WT mice following OVX (P<0.05), but were unmodified by
OVX in cKO mice. Gene expression of the bone remodelling markers Rank, Rankl, Opg
and Sost were unaffected by Pdpn deletion. Together, our data suggest that an intact os-
teocyte dendritic network is required for sustaining osteoclast formation and activity in the
oestrogen-depleted state, through mechanisms potentially independent of RANKL expres-
sion. This work will enable a greater understanding of the role of osteocytes in bone loss
induced by oestrogen deprivation.
Introduction
Throughout life our skeleton is continuously remodeled, a process which is under tight regulation so as to
ensure an imbalance in bone formation or bone resorption does not occur. Such imbalance in favour of
bone resorption results in pathological bone loss leading to osteopaenia and osteoporosis. These diseases
dramatically enhance risk of fracture and as such, are a massive worldwide healthcare burden.
Osteoclasts are responsible for the resorption of mineralised bone through the release
of protons for mineral dissolution and enzymes, such as tartrate-resistant acid phosphatase
(TRAP) and members of the cathepsin and matrix metalloproteinase (MMP) families
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Figure 1. Effects of OVX on WT and Pdpn cKO mice
(A) Uterine weight (g). (B) Total body weight (g). Data are presented as mean +− S.E.M for n≥4; *P<0.05; ***P<0.001.
for the degradation of the organic bone matrix. [1] Osteoclasts originate from a haemopoietic lineage and their
differentiation is stimulated by macrophage colony-stimulating factor (M-CSF), and receptor activator of nuclear
factor κ B (RANK)-ligand (RANKL). Despite their opposing functional roles, compelling evidence supports a pivotal
role for osteoblasts in the regulation of osteoclast differentiation. [2] More recently, evidence has also implicated a
critical role for the osteoblast-derived osteocyte in the regulation of osteoclast differentiation via the production of
RANKL. [3,4] Indeed, the selective conditional deletion of RANKL in osteocytes resulted in a marked osteopetrotic
phenotype in skeletally mature mice. [4]
Osteocytes are the most abundant cell type of the adult skeleton. It has long been considered that osteocytes are
formed by the passive entrapment of redundant osteoblasts by osteoid synthesised by their close neighbours [5,6].
The transition from the cuboidal-like osteoblastic morphology to a dendritic shape characteristic of an osteocyte is
however a more active and tightly regulated process than was originally recognised [7,8]. The characteristic dendritic
phenotype enables the osteocyte to form a highly connected syncytium with neighbouring osteocytes and surface
osteoblasts and osteoclasts, and places the osteocyte at the centre of bonemodelling/remodelling regulatory pathways
(for reviews see [9,10]).
We, and others, have previously highlighted the requirement for the transmembrane glycoprotein E11/podoplanin
(Pdpn) tomake the cytoskeletal networkmodifications that are critical for the formation of dendrites during osteocy-
togenesis. This role is consistent with its expression by early embedding osteocytes, thus identifying Pdpn as a factor
which likely contributes to the vital, early stages of osteocyte differentiation [11]. Furthermore, Pdpn expression in
osteocytes is increased in response to mechanical strain in vivo [12] and the formation of dendritic processes is pro-
moted by both Pdpn overexpression and through its stabilisation by proteasome inhibitors [11,13]. In contrast, the
formation of these cytoplasmic processes is abrogated in cells pre-treated with siRNA targeted against Pdpn and in
mice with a bone-specific ablation of Pdpn [14]. From this evidence, it is reasonable to conclude that Pdpn has an
2 © 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 2. Effects of OVX on WT and Pdpn cKO mouse trabecular bone microarchitecture
Micro-CT analysis of tibia trabecular microarchitecture in WT and Pdpn cKO mice in response to OVX (A) Tb. TV (Trabecular tissue
volume; mm3); (B) Tb. BV (Trabecular bone volume; mm3); (C) Tb. BV/TV (Trabecular BV/TV; %); (D) Tb. N. (Trabecular Number;
mm−1); (E) Tb. Th. (Trabecular thickness; mm); (F) Tb. Sp. (Trabecular Separation; mm); (G) Tb. Pf. (Trabecular Pattern Factor;
mm−1); (H) SMI (Structure model index); (I) BMD (g/cm3). (J) Representative images. Data are presented as mean +− S.E.M for n≥5;
*P<0.05; **P<0.01.
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Figure 3. Osteocyte morphology in WT and Pdpn cKO mouse bone
Quantification of osteocyte morphology parameters using phalloidin-Factin staining and 3D rendering. (A) Total number of complete
cell bodies/cm3. (B) Cell body volume (μm3). (C) Total number of dendrites/cm3. (D) Dendrite length (μm). (E) Dendrite volume (μm3).
Data are represented as mean +− SEM. *P<0.05, **P<0.01, ***P<0.001.
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important functional role in the formation of dendritic processes which are a key feature of the differentiating osteo-
cyte. Nonetheless, important gaps remain in our understanding of the essential role played by Pdpn in full osteocyte
function; in particular the control of osteoblast and osteoclast actions during the bone remodelling process.
Global deletion of Pdpn is perinatally lethal due to the essential role of Pdpn in lung and epithelial cell function [12].
Therefore, in order to test our working hypothesis that Pdpn drives osteocytogenesis and thus regulates bone remod-
elling, we have utilised our previously characterised osteocalcin (OC)-Cre driven bone-specific Pdpn hypomorphic
deletion inmice [14] (conditional knockoutmice (cKO)) to compare the effects of ovariectomy (OVX)-induced bone
loss in cKO to wild-type (WT) mice.
Materials and methods
Animals
Bone-specific Pdpn conditional hypomorphic knockout mice (cKO; ∼70% reduction in protein Pdpn expression)
were generated as previously described under the control of the OC-Cre promoter [14]. OC-Cre mice (WT) were
used as controls. Mice were kept in polypropylene cages, with light/dark 12-h cycles, at 21+− 2◦C, and fed ad libitum
with maintenance diet (Special Diet Services, Witham, U.K.). All experimental protocols were approved by Roslin
Institute’s Animal Users Committee (A650) and experiments were conducted at the Roslin Institute, University of
Edinburgh. Animals were maintained in accordance with U.K. Home Office guidelines for the care and use of labo-
ratory animals.
OVX model of enhanced bone remodelling
At 10 weeks of age, female cKO and WT mice were subjected to either OVX (n=6/genotype) or sham operation
(n=6/genotype), with isoflurane anaesthesia. Tissues were collected 4 weeks post-surgery (14 weeks of age) following
exsanguination under terminal anaesthesia. Uterine and body weights were assessed at killing.
Histological analysis
Right femora were fixed for 24 h in 4% formaldehyde in phosphate buffered saline (PBS) and stored in 70% ethanol.
Samples were decalcified in 10% ethylenediaminetetraacetic acid (EDTA) for 21 days at 4◦C, with the solution
changed every 4–5 days. Samples were washed in PBS, bisected in the sagittal plane, processed to paraffin wax using a
Leica (Wetzlar, Germany) ASP300S Tissue Processor, and embedded in wax on the medial cut surface. A Leica rotary
microtome was used to cut 3-μm sections which were mounted on Superfrost glass slides (Thermo Fisher Scientific,
U.S.A.). Slides were stained with H&E and Goldner’s Trichrome using standard protocols. For TRAP staining 70 mg
napthol AS-TR phosphate (Sigma) was dissolved in 250 μl N-N dimethyl formamide (Sigma) and added to 50 ml of
0.2 M sodium acetate buffer pH 5.2. A total of 115 mg sodium tartrate dihydrate (Sigma) and 70 mg fast red salt TR
(Sigma) were dissolved into this solution and slides were incubated at 37◦C for 2 h. Sections were counterstained in
Meyer’s Haematoxylin (Sigma), washed in distilled water and mounted in aqueous mounting medium (Vector Labs).
Slides were imaged using aNanoZoomer XR slide scanning system (Hamamatsu Photonics, Japan). Histomorphome-
try was performed using the BIOQUANTOSTEO (BIOQUANT ImageAnalysis Corporation, Texas, U.S.A.) software
package using the approved ASBMR histomorphometry nomenclature (three sections/mouse; WT sham n=6, WT
OVX n=5, cKO sham n=6, cKO OVX n=4) [15].
Phalloidin staining
Wax embedded 10-μm sections were washed in PBS twice for 5 min each, and incubated with 0.1% Triton-X 100
(Sigma–Aldrich) for 30 min and then rinsed with PBS. Slides were then incubated with Alexa Fluor 488–conjugated
phalloidin (1:500; Abcam, Cambridge, U.K.) for 1 h. Bone sections were washed in PBS andmounted in ProlongGold
(Thermo Fisher Scientific, U.S.A.). Preparations were allowed to dry at room temperature for 12 h. Optical sections
were taken using the LSM 880 Airyscan confocal laser scanningmicroscope using the 488 nm laser excitation and de-
tection settings from 493 to 634 nm. Z-stacks were produced with optimal Nyquist overlap settings using a 63×/1.4na
oil immersion lens. Voxel sizes were 0.043 × 0.043 × 0.5 μm in x, y, z planes respectively. A comparable region of
interest was analysed for osteocyte parameters in all samples located in the diaphyseal cortical bone. Image stacks
were imported into Bitplane Imaris 9.3.0 software and algorithms were created with Imaris FilamentTracer to render
and measure dendritic processes. Surface rendering was used for osteocyte cell body measurements.
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Micro-computed tomography analysis
Right tibiae were dissected and frozen at −20◦C in dH2O until required. The laboratory scans were performed
with a 1172 X-Ray Microtomograph (Bruker, Belgium) to evaluate the epiphyseal trabecular bone microarchitec-
ture. High-resolution scans with an isotropic voxel size of 5 μmwere acquired (50 kV, 0.5 mm aluminium filter, 0.6◦
rotation angle, 2 frame averaging). The scans were reconstructed using NRecon software (Bruker) and filters were
applied to the images prior to reconstruction to remove artefacts, including beam-hardening and ring artefacts. A
1000-μm section of the metaphysis 250 μm subjacent to the growth plate was taken for analysis of trabecular bone. A
500-μm section of the mid-diaphysis, 3735 μm subjacent to the growth plate, was segmented for analysis of cortical
structure. Data were analysed with CtAn software (Bruker). To assess bone mineral density (BMD), BMD phantoms
of known calcium hydroxyapatite mineral densities of 0.25 and 0.75 g/cm3 were used.
Serum markers of bone formation and resorption
Blood samples from WT and cKO mice were obtained by cardiac puncture under terminal anaesthesia and serum
samples were prepared by centrifugation at 1000×g for 10 min at 4◦C. Markers of bone formation (P1NP) and bone
resorption (Ctx) were quantified by ELISA according to themanufacturer’s instructions (AMS Biotechnology, Abing-
don, U.K.).
RNA extraction and quantitative real-time PCR
Left femurs had their marrow removed by centrifugation before being homogenised in Qiazol reagent (Qiagen) and
total RNA was extracted using an RNeasy mini lipid kit (Qiagen), according to the manufacturer’s instructions. Re-
verse transcriptionwas completed using Superscript II reverse transcriptase (Invitrogen) and gene expression analysis
was carried out by RT-qPCR performed on a Stratagene Mx3000P real-time qPCRmachine (Stratagene, Santa Clara,
U.S.A.) using PrecisionPlus qPCR mastermix with SYBR Green (Primer Design, Southampton, U.K.). Relative gene
expressionwas calculated using theCt method [16]. Each cDNA samplewas normalised to the housekeeping gene
Gapdh (sequences not disclosed; Primer Design). Reactions were performed with gene-of-interest primers (5′–3′):
Rankl (Tnfsf11) F - CGCCAACATTTGCTTTCGG, R - TTTTAACGACATACACCATCAGC; Opg (Tnfrsf11b):
F - AAATTGGCTGAGTGTTTTGGTG, R - CTGTGTCTCCGTTTTATCCTCTC; Sost: F - TGAGAACAACCA-
GACCATGAAC, R - TCAGGAAGCGGGTGTAGTG (Primer Design) and Rank (Tnfrsf11a): F - GCGCAACAGT-
GTTTCCACAG, R - CGCTTGGATCACAGTAAGGCT (Merck).
Statistical analysis
Data were analysed by one-way analysis of variance, Student’s t test or a suitable nonparametric test using GraphPad
Prism 6 and following normality checks. Data are expressed as the mean +− S.E.M. Results were analysed blindly.
P<0.05 was considered to be significant and noted as *; P-values of <0.01 and <0.001 were noted as ‘**’ and ‘***’
respectively.
Results
OVX of Pdpn cKO and WT mice
Ten-week old WT and cKO mice were subjected to either OVX or sham surgeries. To evaluate the efficacy of the
surgery, uterine weights were examined 4 weeks post-surgery. The effect of OVX was similar in both the cKO and
the WT, with both genotypes exhibiting a 30–40% reduction (P<0.001) in uterine weight in comparison with the
sham operatedmice (Figure 1A). Interestingly the uterine weight of the sham operated cKOmice was higher than the
equivalent control mice (P<0.05). No differences were observed in the total body weight between genotypes and/or
surgeries (Figure 1B). These results confirm the success of the OVX and that the hypomorphic deletion of Pdpn does
not modify the uterine response to decreased oestrogen.
Bone microarchitecture changes in response to OVX with Pdpn deletion
OVX caused modest changes to the trabecular microarchitecture of cKO and WT mice compared with their equiv-
alent sham operated control mice. Trabecular BV, trabecular number and trabecular thickness were all slightly di-
minished 4 weeks post-OVX in both genotypes and, although apparently more marked in cKO mice, these changes
did not reach statistical significance (Figure 2A–E). A significant difference between genotypes was observed in the
trabecular pattern factor (P<0.05; Figure 2G), indicating a more markedly disconnected trabecular structure in the
Pdpn cKO mice than in WT mice following OVX (P<0.01; Figure 2G). This correlates closely with the structure
6 © 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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model index which was also significantly increased in Pdpn cKO mice with OVX (P<0.01; Figure 2H). No effects
of genotype or OVX were observed in trabecular BMD (Figure 2I). Cortical bone analysis indicated a significant
decrease in BV/TV in WT mice with OVX (P<0.01), however no effect was observed in Pdpn cKO mice (Supple-
mentary Figure S1). A modest decrease in cross-sectional thickness was also observed with OVX in WT mice, and
this was significantly decreased in Pdpn cKO mice (P<0.05; Supplementary Figure S1). No significant differences
were observed in other cortical bone parameters (Supplementary Figure S1).
OVX induces alterations in osteocyte morphology in WT and Pdpn cKO
mice
To further delineate the association between Pdpn and osteocyte formation with OVX, we next performed phalloidin
staining of F-actin in WT and cKO cortical bone. Subsequent 3D rendering and quantitative analysis of osteocytes
confirmed our previously published data:modest decreases in the total number of cell bodies (Figure 3A) and the total
number of dendrites (Figure 3C), and significant decreases in cell body volume (P<0.001; Figure 3B), and dendrite
length (P<0.05; Figure 3D) in sham-operated cKOmice comparedwithWTwere observed. Interestingly, a significant
increase in dendrite volume was noted in cKO mice compared with WT (P<0.05, Figure 3E). In WT mice, OVX
significantly increased the cell body volume (P<0.01; Figure 3B) and dendrite volume (P<0.001; Figure 3E). Similar
trends were seen in cKO mice with OVX, with significant increases in cell body volume (P<0.001; Figure 3B) and
dendrite length (P<0.001; Figure 3D) observed.
Gene expression of bone remodelling markers are unaffected by
hypomorphic deletion of Pdpn
The RANK/RANKL/osteoprotegrin (OPG) axis is major influence on bone remodelling and if the RANKL/OPG
ratio becomes imbalanced then osteopaenia can result. Therefore we examined whether OVX-related changes in the
expression of Opg , Rankl and Rank were affected by Pdpn deletion. Although trends were seen for increased Rankl
and Opg expression in OVX mice, no statistically significant differences were observed between WT and cKO mice
(Figure 4A,B). Similarly, no significant differences were observed in the expression of Rank (Figure 4C), and changes
the Rankl/Opg ratio in response to OVX were similar in WT and cKO mice (Figure 4D). Sclerostin is a negative
regulator of Wnt signalling and bone formation and is down-regulated in bones from OVX mice. However, in this
present study we noted that although this increase did not reach significance, Sost expression was somewhat raised
by OVX in both WT and cKO mice (Figure 4E).
Deletion of Pdpn protected against increased osteoclast numbers with
OVX
Histological assessment of TRAP activity inWTmice following sham andOVX surgeries revealed an expected signif-
icant increase in osteoclast number per bone surface upon OVX surgery (P<0.01 in comparison with sham operated
WT mice; Figure 5A,B). In contrast, the cKO mice appeared to be protected from the OVX-induced increase in os-
teoclast number, which instead was similar in OVX and sham-operated cKOmice (Figure 5A,B). A significant differ-
ence in osteoclast number per bone surface was also observed betweenWT and cKOOVXmice (P<0.05; Figure 5B).
Serum levels of the resorption marker Ctx were also significantly increased in WT mice following OVX surgery but
remained unchanged in cKO mice following OVX surgery (Figure 5D). In contrast, both osteoblast number (Figure
5C) and serum P1NP, a marker of bone formation, were unaffected by OVX surgery and were similar inWT and cKO
OVX mice (Figure 5E).
Discussion
This manuscript utilised our previously characterised Pdpn cKO mice to examine the effects of OVX-induced bone
resorption in an attempt to decipher the in vivo role of Pdpn on the bone remodelling process. [14] Here we found
that while the hypomorphic deletion of Pdpn had no marked effect on OVX-induced bone phenotype, at the time
point studied it protected against OVX-related increases in osteoclast number and the Ctxmarker of bone resorption.
The vast osteocyte dendritic network is critical for cell–cell communication in bone, maintaining cell viability and
allowing the transfer of nutrients and waste products [10]. We and others have previously shown that Pdpn promotes
osteocytogenesis and dendrite formation in vitro [11,12]. Similarly, we have previously shown that stabilisation of
Pdpn protein, through inhibition of endogenous targeted proteasome activity, promotes dendrite formation in vitro
[11]. By using the cre-LoxP system targeted to exon 3 of the Pdpn gene, we have recently generated bone-specific
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 4. Gene expression in WT and Pdpn cKO mouse bone
RT-qPCR analysis of (A) RANKL (Tnfsf11), (B) OPG (Tnfrsf11b), (C) RANK (Tnfrsf11a), (D) RANKL:OPG ratio, (E) sclerostin (Sost).
Data are presented as mean +− S.E.M for n≥5.
8 © 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 5. Effects of OVX on WT and Pdpn cKO mouse bone histology
(A) Representative micrographs of WT and cKO tibiae following sham or OVX surgery, 20× magnification. Osteoclasts marked with
black arrowheads. Histological analysis of cell counts in sham vs OVX bones. (B) Number of osteoclasts/bone surface. (C) Number
of osteoblasts/bone surface. (D) Concentration of Ctx (marker of bone resorption). (E) Concentration of P1NP (bone formation).
Data are presented as mean +− S.E.M for n≥5; *P<0.05; **P<0.01. Scale bars represent 200 μm.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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(OC-Cre) conditional knockdown mice. We revealed that while Pdpn deletion did not affect osteocyte differentia-
tion in vivo, a vital role for Pdpn in the formation of full length dendritic processes was observed [14]. Here, our data
confirm this and suggest that the hypomorphic deletion of Pdpn and the subsequent inadequate dendrite formation,
quantified by phalloidin staining for F-actin, does not affect OVX-induced changes in the trabecular bone microar-
chitecture. Interestingly a modest increase in the total number of dendrites was observed in cKO mice upon OVX
and this therefore may have influence on the ability to respond to skeletal load, but its relevance to the regulation of
bone remodelling needs further investigation.
Numerous studies have reported the detrimental effects of oestrogen deficiency on osteocyte viability. Indeed, oe-
strogenmaintains osteocyte viability and its depletion inOVXresults in regional osteocyte apoptosis in animalmodels
and in human bone biopsies [17–19]. Inhibition of osteocyte apoptosis through administration of the pan-caspase
inhibitor QVD prevented increases in the osteoclastic resorption normally observed with OVX, thus suggesting a key
role for osteocyte apoptosis in the initiation of endocortical remodelling in response to oestrogen deficiency [19].
Consistent with this, here we observed modest yet non-significant decreases in the total number of osteocyte cell
bodies with OVX inWTmice. Therefore, future studies examining the viability of the osteocytes in our model would
be of great interest. In particular, it would be interesting to see if our cKOmice exhibit decreased osteocyte apoptosis
and hence are protected against OVX-induced increases in osteoclast activity.
Osteocytes play an integral role in maintaining bone homoeostasis by regulating bone modelling and remodelling
through communicating with bone-resorbing osteoclasts via RANKL production. [3,4] Osteoclasts are specialised
multinucleated cells that arise from bone marrow precursors and their differentiation is promoted by RANKL. In-
deed the targeted disruption of RANKL in mice results in severe osteopetrosis [3,20]. OVX in mice stimulates bone
resorption by increasing osteoclast formation and activity due to decreased oestrogen levels as is seen in women with
postmenopausal osteoporosis. Here we observed expected increases in osteoclast number in WT mice subjected to
OVX. However, Pdpn cKO mice exhibited a protection against OVX-induced increases in osteoclast number as well
as activity, as indicated by TRAP activity and serum levels of the bone resorption marker Ctx respectively. This could
be due, in part, to the known disruption to the osteocyte dendritic network previously reported in Pdpn cKO mice
[14] and thus infer a decreased capacity to promote osteoclastogenesis through ineffective RANKL production by os-
teocytes lacking Pdpn. Our gene expression data suggested that no significant differences were observed in RANKL
in either WT or Pdpn cKO mice, however this may be due to RANKL expression not being exclusive to osteocytes.
Indeed RANKL can be produced by stromal cells, osteoblasts, T lymphocytes and B lymphocytes in bone [21]. Fur-
thermore, it has been reported that osteoblasts are the major source of RANKL during oestrogen deficiency and thus
suggest that the lack of changes in RANKL expression which we observe are independent of the osteocyte network
[22]. A focus in future studies could be to further delineate this source of RANKL and could correlate changes in gene
expression to that of protein expression for example through immunohistochemical labelling.
Compelling evidence for a role for osteocytes in regulating bone remodelling also comes from the discovery that
osteocytes, deep in calcified bone, produce sclerostin, a Wnt inhibitor and potent negative modulator of bone for-
mation [23–25]. Indeed, sclerostin has been implicated as a regulator of the differentiation from late osteoblast to
pre-osteocyte, which antagonises Wnt signalling through binding to the Wnt co-receptors, low-density lipoprotein
receptor-related proteins 5 and 6 (LRP5 and LRP6), thereby leading to β-catenin phosphorylation and subsequent
degradation [26]. The therapeutic potential of targeting sclerostin has recently been exploited as an anabolic treat-
ment for osteoporosis [27–30]. Here we observed trends toward increases in bone sclerostin mRNA expression in
response to OVX, however, these trends failed to reach levels of statistical significance and no differences were ob-
served between genotypes. This is consistent with our previous study in which we observed that the hypomorphic
deletion of Pdpn exerted no effect on sclerostin levels in vivo, and failed to modify osteocyte number, shape or size
in these mice [14].
In summary, our data confirm a role for Pdpn in OVX-induced bone remodelling and that an intact osteocyte
network contributes to increases in osteoclastogenesis in OVX-induced bone loss, through mechanisms potentially
independent of RANKL expression. This work will enable a greater understanding of role of osteocytes in bone loss
induced by oestrogen deprivation.
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